Home > Insider Trading > Filing (0000932440-17-000088)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1668243	Urogen Pharma Ltd.	URGN	()	NJ

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1033508	Jay Moorin	C/O Proquest Investments 2430 Vanderbilt Beach Road, #108 - 190 Naples FL 34109	No	No	Yes	No
1225149	Alain Schreiber	C/O Proquest Investments 2430 Vanderbilt Beach Road, #108 - 190 Naples FL 34109	No	No	Yes	No
1431818	Proquest Investments Iv, L.p.	2430 Vanderbilt Beach Road, #108 - 190 Naples FL 34109	No	No	Yes	No
1431819	Proquest Associates Iv Llc	2430 Vanderbilt Beach Road, #108 - 190 Naples FL 34109	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, Par Value Nis 0.01 Per Share	Disposition	2017-11-27	31,491	$41.12	1,419,838	No	4	S	Direct
Ordinary Shares, Par Value Nis 0.01 Per Share	Disposition	2017-11-28	177,807	$40.51	1,242,031	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares.
Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.